Evidence map›Paper›PMID 40525588›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

USP8-Governed MDA5 Homeostasis Promotes Innate Immunity and Autoimmunity.

Qimin Zhang, Shan Huang, Yan He, Weiwei Wang, Chao Tong, Mengru Ma, Manyu Zhao, Lian Yi, Klaus-Peter Knobeloch, Peijing Zhang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Plasma Proteomic Profile of Chemotherapy-Induced Severe Neutropenia: A Pilot Discovery Phase Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Article
  5. Review
  6. USP8-Governed MDA5 Homeostasis Promotes Innate Immunity and Autoimmunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qimin ZhangDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Shan HuangJiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China.
Yan HeNational Engineering Research Center for Nanomedicine, the Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Weiwei WangDepartment of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Chao TongNational Engineering Research Center for Nanomedicine, the Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Mengru MaNational Engineering Research Center for Nanomedicine, the Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Manyu ZhaoNational Engineering Research Center for Nanomedicine, the Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Lian YiNational Engineering Research Center for Nanomedicine, the Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.
Klaus-Peter KnobelochInstitute of Neuropathology, University of Freiburg, 79106, Freiburg, Germany.
Peijing ZhangDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.ORCID https://orcid.org/0000-0003-1586-8710

Funding

China Postdoctoral Science Foundation 2019M652624National Key Research and Development Program of China 2021YFA1201200National Natural Science Foundation of China 32450566National Natural Science Foundation of China 81874116National Natural Science Foundation of China 81901621National Natural Science Foundation of China 82172823National Young Talents Program of ChinaSichuan Science and Technology Program 2024NSFJQ0047
6 · The paper itself

Abstract

The essential cytoplasmic RNA sensor Melanoma Differentiation-Associated protein 5 (MDA5) initiates type I interferons (IFNs) signaling and subsequent immune responses. However, aberrant activation of MDA5 by viral infections or gain-of-function mutations leads to severe autoimmune diseases, for most of which effective treatment is limited. Here, it is shown that inactivation of ubiquitin-specific protease 8 (USP8/UBPy) degrades the MDA5 protein, suppressing antiviral signaling and autoimmunity. It is found that viral infection modulates the AKT-dependent phosphorylation of USP8 at serine 718, which not only promotes the activation of USP8 but also enhances the association between USP8 and MDA5 and the consequent deubiquitination and stabilization of MDA5. Inactivation of USP8 specifically degrades the MDA5 protein regardless of the mutation pattern. Genetic deletion of Usp8 in mice contributes to decreased levels of type I interferons and proinflammatory cytokines. Importantly, inhibition of USP8 or AKT can effectively suppress MDA5-induced autoimmunity in Aicardi-Goutières syndrome (AGS) mice and anti-MDA5-positive dermatomyositis (DM)/systemic lupus erythematosus (SLE) patient cells. Therefore, these results highlight the critical roles of USP8 in innate antiviral immunity against RNA viruses and autoimmunity and provide a potential therapy for treating autoimmune diseases associated with MDA5.

Indexed as

AutoimmunityImmunity, InnateInterferon-Induced Helicase, IFIH1Ubiquitin ThiolesteraseAnimalsAutoimmune Diseases of the Nervous SystemHomeostasisHumansInterferon Type IMiceNervous System MalformationsSignal TransductionIFIH1 protein, humanIfih1 protein, mouseInterferon-Induced Helicase, IFIH1Interferon Type IUbiquitin ThiolesteraseAKTautoimmunitydeubiquitinationinnate immunityMDA5USP8

Identifiers

PMID40525588
PMCPMC12442633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.